Research
Hormonal
The carbohydrate-insulin model, which posits that high carbohydrate intake causes hyperinsulinemia leading to fat storage and weight gain, is experimentally falsified because low-carbohydrate diets fail to produce the expected fat loss or sustained increase in energy expenditure.
Do not rely on the carbohydrate-insulin model to explain weight loss. Low-carb diets do not inherently increase energy expenditure or fat loss compared to other diets when calories are matched. Focus on sustainable dietary patterns.
StrongRefutesHIGH confidence
Although the clinical investigations of the 'carbohydrate-insulin model' have shown the requisite decreases in insulin secretion and increases in fat oxidation, there has been a failure to achieve the expected fat loss under low-carbohydrate feeding.
Why this rating
Based on controlled inpatient feeding trials and meta-analyses.
Source
Low-carbohydrate diets and cardiometabolic health: the importance of carbohydrate quality over quantity
John L. Sievenpiper · Nutrition Reviews · 2019
DOI 10.1093/nutrit/nuz082
narrative_reviewCited 136×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High-quality carbohydrate diets (emphasizing whole grains, pulses, fruit, low glycemic index/load, and high viscous fiber) decrease intermediate cardiometabolic risk factors and are associated with reduced incidence of diabetes, cardiovascular disease, and mortality, whereas low-carbohydrate diets show no long-term superiority for weight loss or sustained glycemic control.Strong
- Sugars are not inherently harmful; their effect on cardiometabolic health depends on energy balance and food source. Sugar-sweetened beverages cause harm due to excess energy, while sugars in high-quality foods (fruit, yogurt, whole grain cereals) provide benefit when substituted for refined starches.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →